Key statistics
On Friday, Trevi Therapeutics Inc (TRVI:NMQ) closed at 2.89, -27.75% below its 52-week high of 4.00, set on Mar 21, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.73 |
---|---|
High | 2.93 |
Low | 2.66 |
Bid | 2.88 |
Offer | 2.90 |
Previous close | 2.73 |
Average volume | 642.71k |
---|---|
Shares outstanding | 76.87m |
Free float | 75.96m |
P/E (TTM) | -- |
Market cap | 209.84m USD |
EPS (TTM) | -0.4412 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 20:47 GMT.
More ▼
- Trevi Therapeutics to Participate in Piper Sandler 36th Annual Healthcare Conference
- Trevi Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
- Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024
- Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough
- Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences
- Trevi Therapeutics Provides Update on Haduvio's Clinical Development Program
- Trevi Therapeutics Announces Appointment of James V. Cassella, Ph.D., as Chief Development Officer
- Trevi Therapeutics Announces Additional Analyses of Cough Relief Time from Ph2a CANAL Trial Accepted for Oral Presentation at CHEST 2024
- Trevi Therapeutics Announces Oral Presentation on Data from Ph2a CANAL Trial at the European Respiratory Society Congress 2024
- Trevi Therapeutics to Participate in September Investor and Medical Conferences
More ▼